Loading...
Market
What will be J&J's new drug combinations' market share in multiple myeloma treatment by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Market analysis reports from firms like IMS Health or EvaluatePharma
Story
Johnson & Johnson's ($JNJ) New Drug Combinations Show Promise in Multiple Myeloma Treatment
Sep 27, 2024, 12:05 PM
Johnson & Johnson's novel combinations of TALVEY® (talquetamab-tgvs) with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) show promising results in treating patients with relapsed or refractory multiple myeloma. The combinations suggest high response rates and durable responses, including in triple-class refractory patients and those with extramedullary disease. These findings indicate potential advancements in treatment options for this challenging condition. The results are significant for Johnson & Johnson ($JNJ) and its partners, including $GMAB.DC and $GMAB.
View original story
Similar markets
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below $5 billion • 25%
$5 billion to $5.5 billion • 25%
$5.5 billion to $6 billion • 25%
Above $6 billion • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $10 billion • 25%
$10 billion to $15 billion • 25%
$15 billion to $20 billion • 25%
More than $20 billion • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%